FDA Approves Ozempic for Type 2 Diabetes

Share this content:
FDA Approves Ozempic for Type 2 Diabetes
FDA Approves Ozempic for Type 2 Diabetes

WEDNESDAY, Dec. 6, 2017 (HealthDay News) -- A new once-weekly diabetes medication that lowers blood glucose and also helps patients lose weight has been approved by the U.S. Food and Drug Administration.

The once-a-week injection drug Ozempic (semaglutide) is approved for patients with type 2 diabetes. It stimulates the body's insulin production and reduces appetite, the Associated Press reported.

The drug is from Danish company Novo Nordisk. A company-funded study of 1,200 type 2 diabetes patients found those who took Ozempic had average reductions in long-term blood glucose levels at least 2.5 times greater than those who took daily sitagliptin.

Patients who took Ozempic also lost two to three times as much weight as those in the comparison group, the AP reported.

More Information

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

Lab  Companion Tests Perform Similarly for Oncology Analytes

Lab + Companion Tests Perform Similarly for Oncology ...

Findings based on comparison of tests to diagnose oncology-related genetic variants

Ulixertinib Is Active in Patients With Advanced Solid Tumors

Ulixertinib Is Active in Patients With Advanced Solid ...

Responses occurred in patients with NRAS-, BRAF V600-, non-V600 BRAF-mutant solid tumors

Doctors Must Report on at Least 1 Patient, 1 Measure for MACRA

Doctors Must Report on at Least 1 Patient, ...

To avoid Medicare payment penalty in 2019, clinicians must report by Dec. 31, submit by Feb. 28

is free, fast, and customized just for you!

Already a member?

Sign In Now »